Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Phase II Trial of Cisplatin, Irinotecan and Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Conditions
Interventions
Bevacizumab
Cisplatin
+2 more
Locations
4
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Texas Oncology Research
Dallas, Texas, United States
Start Date
July 1, 2009
Primary Completion Date
April 1, 2012
Completion Date
August 1, 2013
Last Updated
November 8, 2022
NCT04550494
NCT04704661
NCT05489211
NCT04674267
NCT05702229
NCT07217704
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions